A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

The combination of drugs targeting Ral and PI3K/AKT signaling has antitumor efficacy in preclinical models of pancreatic cancer. We combined dinaciclib (small molecule cyclin dependent kinase inhibitor with MK‐2206 (Akt inhibitor) in patients with previously treated/metastatic pancreatic cancer. Pat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Transl Sci
Main Authors: Murphy, Adrian G., Zahurak, Marianna, Shah, Mirat, Weekes, Colin D., Hansen, Aaron, Siu, Lillian L., Spreafico, Anna, LoConte, Noelle, Anders, Nicole M., Miles, Tearra, Rudek, Michelle A., Doyle, L. Austin, Nelkin, Barry, Maitra, Anirban, Azad, Nilofer S.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7719383/
https://ncbi.nlm.nih.gov/pubmed/32738099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cts.12802
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker